

Our ref: IG/FOI/FOI.386.25

10 July 2025

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 04 July 2025, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require

For ease of reference your request is set out below and my response follows each question individually.

Your Freedom of Information (FOI) Request and Powys Response (Bold):

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

Powys Teaching Health Board (PTHB) does not have District General Hospital (DGH) services or provide endometrial cancer services. Our residents access their acute and specialist services in DGH's provided by neighbouring health boards in Wales and neighbouring NHS Trusts in England. I therefore recommend you contact them directly for this information, via the following contact details:

Health Trust/Organisation	FOI Contact Details
Gloucestershire Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Midlands Partnership University NHS Foundation Trust	FOI@mpft.nhs.uk
The Robert Jones Agnes Hunt Orthopaedic Hospital NHS Foundation Trust	rjah.foi@nhs.net
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-FOIRequests@nhs.net
The Shrewsbury and Telford Hospital NHS Trust	sath.foi@nhs.net

Pencadlys
Tŷ Glasbury, Ysbyty Bronllys,
Aberhonddu, Powys LD3 0LU
Ffôn: 01874 711661



Headquarters
Glasbury House, Bronllys Hospital
Brecon, Powys LD3 0LU
Tel: 01874 711661

The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS Trust	Freedom.Information@wvt.nhs.uk

Health Board/Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk
Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	Freedomofinformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University NHS Trust	Foi.vunhst@wales.nhs.uk

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli)
- Dostarlimab (Jemperli) AND Chemotherapy
- Hormone therapy (Progesterone or Letrozole)
- Pembrolizumab (Keytruda) monotherapy
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda)
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
- Any other SACT
- Any other Chemotherapy
- Durvalumab with platinum-based chemotherapy
- Pembrolizumab with platinum-based chemotherapy

Not applicable. Please see response to Question 1.

Q3. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?

I can confirm that PTHB does not provide clinical trials for treatment of endometrial cancer.

Under the terms of the Health Board's Freedom of Information procedure, individuals seeking access to recorded information held by the Health Board are entitled to request an internal review of the handling of their requests. If you would like to complain about the Health Board's handling of your request, please contact us directly at the address below or register your complaint via Powys.FOI@wales.nhs.uk

If after Internal Review you remain dissatisfied you are also entitled to refer the matter to the information commissioner at the Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH. Telephone Number: 0330 414 6421.

Yours sincerely



David Farnsworth
Assistant Director, Community Services Group

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.